Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSH | P09668 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 5/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289806 | 0.89 | MAPT (0.43) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL22308325 | 0.88 | MAPT (0.49) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL3410954 | 0.87 | MAPT (0.48) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL29503795 | 0.85 | MAPT (0.43) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL13382341 | 0.85 | TSHR (0.56) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL22307313 | 0.84 | MAPT (0.56) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL22307834 | 0.84 | MAPT (0.46) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL18215408 | 0.84 | KDM4E (0.49) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL8063168 | 0.83 | MAPT (0.48) | MAPTKDM4EALDH1A1HTTMAPK1 | |
| SCHEMBL26623341 | 0.83 | MAPT (0.48) | MAPTKDM4EALDH1A1HTTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010059418-A1 | SUBSTITUTED TRIAZINE AND PURINE COMPOUNDS, METHODS OF INHIBITING CRUZAIN AND RHODESAIN AND METHODS OF TREATING CHAGAS DISEASE AND AFRICAN TRYPANOSOMIASIS | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES (US) | 2010-05-27 | — | — | WO | disclosed |
| US-20100041661-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2010-02-18 | — | — | US | disclosed |
| WO-2009075778-A3 | NONPEPTIDIC INHIBITORS OF CRUZAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-10-15 | — | — | WO | disclosed |
| EP-2079710-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG Life Sciences Ltd. (KR) | 2009-07-22 | — | — | EP | disclosed |
| WO-2009075778-A2 | NONPEPTIDIC INHIBITORS OF CRUZAIN | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2008056897-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | LG LIFE SCIENCES LTD. (KR) | 2008-05-15 | — | — | WO | disclosed |
| WO-2006033551-A1 | CASPASE INHIBITORS CONTAINING DICARBONYLAMINO-ISOXAZOLINE | LG LIFE SCIENCES LTD. (KR) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005035497-A1 | CASPASE INHIBITOR COMPRISING 2-ALKYL-4-OXOBUTANOYL GROUP AND PHARMACEUTICAL COMPOSITION THEREOF | LG LIFE SCIENCES LTD. (KR) | 2005-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041661-A1 | CASPASE INHIBITORS BASED ON PYRIDAZINONE SCAFFOLD | CASP1, CASP2, CASP5 | MAPT 944/4885KDM4E 1498/4885ALDH1A1 3666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.